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AbstrACt 
Introduction Adaptive deep brain stimulation (aDBS), 
based on the detection of increased beta oscillations in the 
subthalamic nucleus (STN), has been assessed in patients 
with Parkinson’s disease (PD) during the immediate 
postoperative setting. In these studies, aDBS was shown 
to be at least as effective as conventional DBS (cDBS), 
while stimulation time and side effects were reduced. 
However, the effect of aDBS on motor symptoms and 
stimulation-induced side effects during the chronically 
implanted phase (after the stun effect of DBS placement 
has disappeared) has not yet been determined.
Methods and analysis This protocol describes a single-
centre clinical study in which aDBS will be tested in 
12 patients with PD undergoing battery replacement, 
with electrodes implanted in the STN, and as a proof of 
concept in the internal globus pallidus. Patients included 
will be allocated in a pseudo-randomised fashion to a 
three-condition (no stimulation/cDBS/ aDBS), cross-over 
design. A battery of tests will be conducted and recorded 
during each condition, which aim to measure the severity 
of motor symptoms and side effects. These tests include 
a tablet-based tapping test, a subscale of the Movement 
Disorder Society-unified Parkinson's disease rating scale 
(subMDS-UPDRS), the Speech Intelligibility Test (SIT) and 
a tablet-based version of the Stroop test. SubMDS-UPDRS 
and SIT recordings will be blindly assessed by independent 
raters. Data will be analysed using a linear mixed-effects 
model.
Ethics and dissemination This protocol was approved 
by the Ethical Committee of the University Medical Centre 
Groningen, where the study will be carried out. Data 
management and compliance to research policies and 
standards of our centre, including data privacy, storage 
and veracity, will be controlled by an independent monitor. 
All the scientific findings derived from this protocol are 
aimed to be made public through publication of articles in 
international journals.
trial registration number NTR 5456; Pre-results.
IntroduCtIon
background and rationale
Deep brain stimulation (DBS) is currently 
one of the most effective advanced treatments 
for patients with Parkinson’s disease (PD). At 
present, conventional DBS (cDBS) provides 
the continuous delivery of fixed-frequency 
and fixed-amplitude electrical pulses through 
the electrodes implanted mostly in either the 
subthalamic nucleus (STN) or the internal 
globus pallidus (GPi).1 2 Although cDBS is an 
effective treatment, it still has limitations in 
terms of efficacy, side effects and efficiency, 
and these have not undergone substantial 
improvements since the implementation 
of cDBS in clinical practice, approximately 
20 years ago.3 However, new DBS systems 
directed to improve current stimulation algo-
rithms are currently under development. 
These systems are often referred to as adap-
tive DBS (aDBS), as they aim to modulate the 
delivery of electrical stimulation, controlled 
by the detection of symptoms, such as tremor, 
or aberrant signals (biomarkers) that have 
been implicated in the pathophysiology of the 
disease.4 The ultimate goal of aDBS systems 
is to reduce the total amount of stimulation 
delivered, in a way in which beneficial effects 
of DBS are enhanced, while side effects are 
reduced.5 Furthermore, decreasing the total 
amount of stimulation delivered will allow to 
extend the battery life(span) of DBS devices.
strengths and limitations of this study
 ► This protocol aims to assess both efficacy and 
side-effect profile of adaptive deep brain stimulation.
 ► The stun effect will not present in the patient popu-
lation to be included in this protocol.
 ► Intraoperative testing will minimise exposure time 
for electrodes and risk of infection.
 ► Testing and washout periods will be limited by the 
intraoperative time available.
 ► The intraoperative setting will limit the tests avail-
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Several biomarkers in PD have been proposed for use 
as a feedback signal for aDBS.6 Currently, the presence 
of prominent beta oscillations (13–35 Hz), in either the 
STN or the GPi, seems to be the most promising since it 
correlates with the severity of bradykinesia and rigidity.7 
Evidence to date suggests that aDBS may be at least as 
effective as cDBS systems, while stimulation time and side 
effects are reduced.8–10 However, virtually all aDBS exper-
iments based on beta oscillations have thus far only been 
tested in the immediate postoperative setting. Although 
aDBS has been evaluated mostly with regard to the STN, 
preliminary evidence indicates that aDBS could be equally 
effective when applied to the GPi.11 The correlation of 
other prominent PD symptoms (such as tremor) with 
beta oscillations is far less robust. Therefore, the impact 
of aDBS on these symptoms is yet to be addressed.12 13
Besides its effect on motor symptoms, a common 
side effect that could potentially be addressed by aDBS 
is stimulation-induced dysarthria. Preliminary data in 
the immediate postoperative phase showed that aDBS 
did not induce dysarthria, in contrast to cDBS.14 Like-
wise, due to the reduction in the total amount of stim-
ulation that occurs in aDBS, this new technology could 
potentially help to tackle DBS-related side effects in 
executive functions, such as impaired response inhibi-
tion.15 16 Patients with PD treated with DBS are prone to 
make more mistakes in inhibitory control tests (eg, the 
Stroop task).17 Response inhibition is a fundamental 
cognitive function, and its impairment could lead to 
impulsive conduct.18 For that reason, it is possible that 
stimulation-related impulsivity is the result of an impair-
ment of response inhibition caused by DBS.19 20 It was 
first proposed that this side effect was due to unintended 
stimulation of limbic areas of the STN.21 However, it has 
been shown recently that DBS has a positive effect on 
risk-reward decision behaviour in patients with PD, and 
that such an effect was mostly dependent on stimulation 
of the motor part of the STN.22 This finding indicates 
that at least some of the non-motor effects of DBS are 
mediated through direct stimulation of the motor part 
of the STN. This is supported by increasing evidence that 
indicates that the motor and non-motor functions of the 
STN are not perfectly segregated.23 It has been shown 
that beta oscillations in the motor STN play a significant 
role in adequate response inhibition.24 For that reason, 
stimulation-induced impulsivity could be the result of an 
excessive beta suppression produced by continuous stim-
ulation. Therefore, aDBS might be used as an additional 
option to address stimulation-induced impulsivity, since 
aDBS has the potential to provide a functional selectivity, 
by only triggering stimulation based on (primarily) motor 
biomarkers (eg, beta oscillations), only when a threshold 
is exceeded. As a result, only excessive beta activity would 
be suppressed.
objectives
The aim of this study is to assess whether aDBS provides 
a similar motor improvement compared with cDBS, while 
limiting the presence of stimulation-induced side effects 
in patients with chronically implanted electrodes. Stimu-
lation efficacy is assessed using a battery of tests aiming to 
measure the motor response to different conditions and 
the severity of dysarthria and/or impulsivity. The goals of 
this protocol are summarised in three questions:
1. Is aDBS at least as efficacious as cDBS in terms of mo-
tor improvement?
2. Is the speech-related and response inhibition side-ef-
fect profile of aDBS lower than that of cDBS?
3. What is the amount of stimulation provided in aDBS 
compared with cDBS?
trial design
This protocol describes an exploratory study in which 
patients with PD with DBS electrodes implanted in the 
STN are allocated to a three-condition (no stimulation 
(NoStim)/cDBS/aDBS), cross-over design (figure 1). 
The conditions are pseudo-randomised in a 2:1:1 format, 
in such a way that for every two patients who start with 
no-stimulation, one patient will receive aDBS first and one 
will have cDBS first. The main reason for this proposed 
pseudo-randomisation is to minimise the impact that 
an incomplete washout effect derived from stimulation 
could have on the scores of NoStim condition, as this 
condition is the baseline for the comparison of the effect 
of the two stimulation modalities. In four patients, stimu-
lation conditions will be separated by a NoStim condition 
to minimise the carryover effect that cDBS could have 
on aDBS (or vice versa). Lastly, NoStim will be the last 
condition in two patients in order to partially balance the 
effects of training or fatigue on the tasks. Additionally, 
pilot data could be collected from two patients in order 
to explore the effects of aDBS on the GPi.
The performance of several tasks during the three 
conditions will take place during the battery replacement 
surgery, when a temporal externalisation of the DBS 
extension wires is performed. This means that subjects 
to be included have had their DBS electrodes implanted 
for at least 3–5 years, and therefore the stun effect is 
not present in this patient population. It was decided 
to perform this protocol intraoperatively as it allows the 
surgery to be completed in one session, minimising the 
time that electrodes are externalised and patients are 
exposed to potential risks of infection.
MEthods And AnAlysIs
Methods: participants, interventions and outcomes
Study setting
This is a single-centre study at the University Medical 
Centre Groningen.
Inclusion criteria
 ► Patients with PD with DBS electrodes implanted bilat-
erally in the STN. A maximum of two patients with PD 
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 ► Patients are cognitively capable of performing the 
tests included in this protocol. This item is subjectively 
evaluated during the patient interview, by looking at 
the performance of the candidate when completing 
a trial set of the tablet-based tests used during the 
experiment.
 ► Able to provide written informed consent.
 ► Physical condition that enables 20–30 min of testing. 
This is evaluated according to the clinical records and 
the fragility of the patient (determined by the treating 
neurologist).
 ► Ability to undergo testing in the OFF dopaminergic 
state, determined by the clinical condition of the 
patient after medication withdrawal.
Exclusion criteria
 ► Patients who cannot tolerate battery replacement 
under local anaesthesia (eg, presence of severe OFF 
medication tremor, severe anxiety, etc).
 ► <18 years old.
 ► Clinical disorders or diseases that could interfere 
with clinical assessment (eg, vision impairment that 
Figure 1 Trial design and pseudo-randomisation block. aDBS, adaptive deep brain stimulation; cDBS, conventional DBS; 
GPi, internal globus pallidus; PD, Parkinson's disease; subMDS-UPDRS, subscale of the Movement Disorder Society-unified 
Parkinson's disease rating scale; SIT, Speech Intelligibility Test. 
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cannot be corrected with glasses, severe limb move-
ment restriction).
 ► Cognitive impairment sufficient to prevent the patient 
to consider and retain the necessary information to 
make a decision regarding the participation in the 
study.
Investigational device
The responsive (closed loop) aDBS is delivered through 
a custom-made stimulation-amplifier which allows local 
field potentials (LFPs) to be recorded during the appli-
cation of DBS. With this device, LFPs are filtered in real 
time around a subject's specific beta frequency (±3 Hz 
around peak).9 Afterwards, a median threshold is selected 
in order to deliver monopolar stimulation every time 
that beta activity in the rectified filtered LFP exceeds the 
predefined threshold. Stimulation pulses are charge-bal-
anced and asymmetric, mirroring the waveform of the 
standard clinical Medtronic Activa PC. Pulses are deliv-
ered at 130 Hz with a pulse width of 60 µs (standard clin-
ical parameters) using a ramping period of 250 ms at onset 
and offset in order to help limit the presence of paraes-
thesias, autonomic or other non-specific side effects, such 
as dizziness or nausea.25 From the four contacts available 
for each electrode lead, two electrodes are required to 
perform bipolar LFP recordings (either contacts 0–2 or 
1–3), while one electrode (in between the two recording 
electrodes) is left available for stimulation (either contact 
1 or 2). The stimulation-amplifier has been built to strict 
safety guidelines (Report 90 BS EN60601-1 safe design, 
construction of medical equipment) and extensively 
tested,8 9 11 26 and found to be safe and reliable.
Procedure
Patients have to skip at least one medication dose and 
are not allowed to be under the effect of prolonged-re-
lease dopaminergic medication in order to be classified 
as OFF medication before surgery. Patients are brought 
to the operating theatre for their battery replacement 
procedure. After the battery is exposed, the old battery is 
detached from the DBS electrodes and explanted. At this 
moment, two temporary wires are attached to the DBS 
electrode extension cables and connected to a combined 
stimulator and amplifier (see previous section). A brief 
rest recording of 30–60 s is performed from each of 
the two bipolar montages (0–2 or 1–3) available for 
each hemisphere. Power spectral density estimates are 
obtained from each rest recording, and the bipolar 
contact pair (0–2 or 1–3) per hemisphere with the highest 
beta peak power is selected. Monopolar cDBS is then 
titrated using the available contact located between the 
selected recording contacts. The voltage for monopolar 
stimulation is titrated initially based on an approximation 
of the voltage used in clinical practice for each individual 
patient (independently of the montage used in clinical 
practice). Voltage is increased or decreased according to 
the presence of side effects, clinical effect and interfer-
ence with LFP recordings (in practice, we have seen that 
voltages>3.5 V are more prone to cause interference with 
the recordings, and these are also rare stimulation param-
eters in clinical practice). Once an optimum stimulation 
voltage is established, the patients are assigned to each of 
three counterbalanced conditions in which the patient is 
either stimulated with aDBS or cDBS, or not stimulated, 
separated by washout periods of 1–3 min, according to 
the remaining time available. Stimulation parameters 
(voltage, frequency, pulse width and contact selection) 
remain constant for both aDBS and cDBS, differing only 
in the timing of stimulation delivered according to beta 
detection. As battery replacements are performed under 
local anaesthesia, we aim to limit the duration of the 
experiment to a maximum of 25–30 min.
Clinical tests and outcomes
Each patient performs the following tasks in each of the 
three pseudo-randomised conditions:
a. Tablet-based tapping test: several analogue and dig-
ital versions of the tapping test have been validated 
to objectively measure the presence of bradykinesia 
in patients with PD.27–29 We developed a custom tab-
let-based finger tapping test using the PsyPad plat-
form.30 In this test, a tablet is presented to the patient, 
in which two squares appear at the left and right sides 
of the screen (figure 2). The patient then has to press 
the squares in an alternating pattern. We tested this 
set-up, as a proof of principle, on a patient with PD 
who underwent battery replacement,26 using 50 tap-
ping iterations per condition. In order to optimise the 
time available for the battery of tests, it was decided 
to reduce the iterations to 20. Since the duration of 
each iteration was approximately 500 ms, 20 iterations 
(10 back-and-forth screen tapings) will be roughly 
equivalent to 10 finger tapings, which is the amount 
of taps required to measure tapping items from the 
Movement Disorder Society-unified Parkinson's dis-
ease rating scale (MDS-UPDRS).
b. Subscale of the MDS-UPDRS (subMDS-UPDRS)31 (Part 
III, items 3.4, 3.5, 3.6, 3.15, 3.17 a, b): as patients are ly-
ing on the operating table during the experiment, only 
selected items can be performed by the patients. The 
items that are included and filmed are finger tapping, 
hand movements, pronation-supination, rest tremor 
and postural tremor.
c. Speech Intelligibility Test (SIT): this is a modified ver-
sion of the Assessment of Intelligibility for the Dysarthric 
Speech.32 33 In this test, the patient is instructed to read 
out a list of 18 sentences (approximately 110 words per 
condition), while the speech is recorded with a mo-
bile application. The words that form each sentence 
are randomly chosen, taking into account that each 
sentence must follow the correct order of a proper 
grammatical construction. Voice recordings are sent to 
a speech therapist, who blindly evaluates the sentenc-
es and writes them down. Afterwards, the sentences 
written by the speech therapist are compared with the 
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original list, and the amount of words that coincide are 
expressed as a percentage of the total words.
d. Tablet-based version of the Stroop test34: in this test, 
20 colour words are presented to each patient in a se-
quential order, and each word is coloured as shown in 
figure 3. From those 20 words, five are coloured in the 
same colour as the word written (congruent), while 
15 words are coloured in a colour different from the 
word written (incongruent). We chose an unbalanced 
design as our main focus is the effect of stimulation 
on incongruent words between conditions, rather 
than the effect of stimulation between congruent and 
incongruent words. For each word presented, four but-
tons are presented at the bottom of the tablet screen, 
each containing different colour words. The patient 
has to select the button containing the colour word 
presented on the screen, independently of the colour 
in which the word is coloured in. Reaction times and 
accuracy for each trial are directly uploaded to an on-
line database, from which they can be extracted for 
data analysis.
order of the tests
After the battery is exposed, and before the performance 
of the clinical tests can start, a number of preparations are 
required in order to programme the aDBS (see the Proce-
dure section). This requirement can lead to individual 
differences in the time available to perform the clinical 
tests due to the maximum amount of intraoperative time 
allowed for this experiment. Therefore, the sequence in 
which the clinical tests are performed on each condition 
is initially ordered according to the approximate time it 
takes the patient to perform each of them, the suggested 
order being as follows: (1) tablet-based tapping test, (2) 
subMDS-UPDRS, (3) Speech and Intelligibility Test (SIT), 
(4) tablet-based version of the Stroop test. If during the 
course of each individual experiment it is considered that 
the time will not be sufficient for a patient to complete 
the full protocol, only the first test(s) could be selected to 
be performed in order to ensure that at least one of the 
tests will be completed for each of the three conditions.
sample size
According to previous studies,35 a difference of approx-
imately four points in the total motor UPDRS could be 
considered clinically significant (3.7% of the total scale). 
This would be roughly equivalent to a limit of 1.5 points 
on a 10-item UPDRS scale, which is the one used in this 
protocol. Based on pilot data conducted in Oxford/
London on four patients,9 aDBS scores had an standard 
Figure 3 Example of two trials of the tablet-based Stroop test with congruent (left) and incongruent (right) conditions.
Figure 2 Example of a trial of the tablet-based bradykinesia test.
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error of approximately two points (SD of 4). This is 
roughly equivalent to an SD of 1.5 points on a 10-item 
UPDRS scale. Using an α of 0.05, a power (1−β) of 0.8 and 
assuming similar variances, a sample size of 12 patients 
would be necessary to demonstrate that the efficacy of 
aDBS is not inferior to cDBS, while providing the poten-
tial benefits of facilitating programming, battery life opti-
misation and the potential to reduce stimulation-induced 
side effects. A potential extension of two patients (14 
patients in total) would be pursued in order to explore 
the potential effects of aDBS on patients with electrodes 
implanted on the GPi.
recruitment
Patients who are scheduled for a battery replacement at 
the University Medical Centre Groningen are contacted 
by telephone 2 weeks before their hospital admission to be 
informed about the study. Complementary written infor-
mation is sent by mail to patients who show an interest 
in participating in the study. At the time of hospital 
admission, each patient is personally approached by one 
of the members of the research team, if they meet all of 
the inclusion criteria and none of the exclusion criteria. 
Patients who decide to participate in the study will then 
be given the opportunity to ask further questions and 
invited to sign the consent form.
Methods: assignment of interventions
Allocation
The ultimate goal of the allocation procedure is to have 
a pseudo-randomisation in which all the possible combi-
nations of the block design are covered (ie, 2:1:1, see 
the Trial design section, figure 1). For that reason, patients 
will be sequentially allocated to each possible pseudo-ran-
domisation scenario until 14 patients are allocated. Only 
successful bilateral measurements will be considered in 
the pseudo-randomisation list. At first, a pseudo-rando-
misation of 3:1:1 (10 patients) will be set as the allocation 
goal in order to ensure that all conditions of the pseu-
do-randomisation could be met by mid-2019. Depending 
on the number of aborted experiments and the dead-
line for inclusion, two patients more may potentially be 
included to achieve the 2:1:1 pseudo-randomisation.
blinding (masking)
Patients will be blinded to the stimulation condition. 
Video and voice recordings will be taken for the subMDS-
UPDRS and SIT parts, and will be blindly evaluated by 
two neurologists experienced in movement disorders and 
a speech therapist, respectively. Analysis of tablet-based 
outcomes will be automated and matched across the 
three conditions.
Methods: data collection, management and analysis
Data management
Data are stored on a central database using REDCap 
storage system, being accessible only to the authorised 
personnel involved in this study.
statistical methods
Simple scores from the subMDS-UPDRS, tablet-based 
tapping test, SIT and Stroop test during aDBS versus cDBS 
or NoStim will be checked for normality using Q-Q plots, 
and if normally distributed, will be compared using a 
linear mixed-effects model. If the data are non-normally 
distributed, a data transformation will be applied, or a 




The experimental procedure does not substantially 
expose patients to increased risks, as there are no extra 
surgical procedures required, and patients are stimulated 
only with less electrical current than in their conven-
tional setting. Given that the experiments take place in 
the operation room, and only add less than 30 min to the 
total surgery duration, there is no significant added risk 
of infection. Since patients are tested in the OFF dopami-
nergic state, this exaggerates their symptoms to certain 
extent. However, DBS remains active until the moment of 
the surgery, which limits the impact of medication discon-
tinuation. In previous aDBS studies, electrodes were 
exposed for hours or days9 10 without any increased risk of 
infection. Therefore, as battery replacement is completed 
in one session, the amount of time in which the extension 
wires are exposed is considerably shortened in this study. 
Nevertheless, infections will be considered an adverse 
event and infection rates monitored.
Monitoring
Data management and compliance to research policies 
and standards of our centre, including data privacy, 
storage and veracity, are verified by an independent 
monitor from a different department within the hospital. 
As this is an investigator-initiated study, the project leader 
submits, once a year throughout the clinical trial, a safety 
report to the accredited local ethics committee. Serious 
adverse events, defined by the Central Committee on 
Research Involving Human Subjects in the Netherlands 
as ‘any untoward medical occurrence or effect that at any 
dose results in death, is life threatening (at the time of 
the event), requires hospitalisation or prolongation of 
existing inpatients’ hospitalisation or results in persistent 
or significant disability or incapacity’, will be promptly 
reported to the corresponding governmental authorities.
Patient and public involvement
In order to make sure that the experiments are as comfort-
able as possible for the subjects, a short Patient Reported 
Outcome (PRO) questionnaire will be conducted on the 
first five patients (figure 4). This PRO consists of five ques-
tions in which patients can indicate whether the commu-
nication was adequate and empathetic and whether the 
procedure was not too demanding, uncomfortable or 
painful. The feedback of these reports will be used to 
evaluate the adequacy of the protocol, and changes will 
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be incorporated into the following study procedures, if 
necessary via an amendment.
EthICs And dIssEMInAtIon
Protocol amendments
The protocol presented here is the fifth version (9 December 
2018) of the original protocol prepared for this study. The 
second version of the protocol (15 September 2015) got the 
approval of the ethical committee after several modifica-
tions of the first version (22 July 2015). In version 3 (12 April 
2017), an attempt was made to include patients undergoing 
new implantations. However, this was dropped in subse-
quent versions, since (a) patients undergoing new implanta-
tions were often considerably fatigued at the moment of the 
measurement and could not perform all the tasks; (b) differ-
ences in total intraoperative time between new implantations 
Figure 4 Example of the Patient Reported Outcome questionnaire form conducted on the participants.
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and battery replacements meant that the time available for 
the measurement was considerably less during new implan-
tations; (c) the stereotactic frame slightly restricted the 
visual field of the patients in new implantations. Version 4 
(7 September 2017) and version 5 were meant to increase 
the total number of patients to be included, as several failed 
or incomplete measurements took place during the initial 
inclusions.
Consent
During the inclusion interview, patients are informed 
that the participation in this study is on an entirely volun-
tary basis, and that they are therefore allowed at any 
moment to withdraw their consent. No economic reward 
is provided for the participation in this study.
Confidentiality
Only indirect personal data from each patient are stored 
as coded information in order to prevent the possibility 
that patient data could be traced back to an individual 
patient. The coding list will be safeguarded in a secured 
facility located in our centre. Data derived from the clin-
ical tests or recordings could be exported only as anony-
mised data to be used for statistical analysis.
Ancillary and post-trial care
Patients are insured up to €650 000 for harm suffered 
directly from trial participation. Details of the insurance are 
provided on the patient information letter of this study. 
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